See more : Jayud Global Logistics Limited (JYD) Income Statement Analysis – Financial Results
Complete financial analysis of Takeda Pharmaceutical Company Limited (TAK) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Takeda Pharmaceutical Company Limited, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Chitec Technology Co., Ltd. (3430.TWO) Income Statement Analysis – Financial Results
- NEXE Innovations Inc. (NEXNF) Income Statement Analysis – Financial Results
- Knaus Tabbert AG (KTA.DE) Income Statement Analysis – Financial Results
- PT Bhakti Agung Propertindo Tbk (BAPI.JK) Income Statement Analysis – Financial Results
- DXI Capital Corp. (DXIEF) Income Statement Analysis – Financial Results
Takeda Pharmaceutical Company Limited (TAK)
About Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan, the United States, Europe, Canada, Latin America, Russia, rest of Asia, and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab, Alofisel, Dexilant, Natpara, Adynovate/Adynovi, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Velcade, Leuplin/Enantone, Adcetris, Vyvansese, Trintellix, and Alunbrig brands. Takeda Pharmaceutical Company Limited has out-licensing agreement with Neurocrine Biosciences, Inc.; collaborations and in-licensing agreements with the University of Texas MD Anderson Cancer Center, Arrowhead Pharmaceuticals Inc., and Ovid Therapeutics Inc.; and collaboration with Evox Therapeutics Ltd., as well as a licensing agreement with ProThera Biologics Inc. It also has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, Selecta Biosciences, BridGene Biosciences, Skyhawk Therapeutics, and StrideBio; and strategic alliances with Egle Therapeutics SAS; Evotec SE; Neurocrine Biosciences, Inc.; Carmine Therapeutics; KSQ Therapeutics; and Anima Biotech. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4,263.76B | 4,027.48B | 3,569.01B | 3,197.81B | 3,291.19B | 2,097.22B | 1,770.53B | 1,732.05B | 1,807.38B | 1,777.82B | 1,691.69B | 1,557.27B | 1,508.93B | 1,419.39B | 1,465.97B | 1,538.34B | 1,374.80B | 1,305.17B | 1,212.21B | 1,122.96B | 1,086.43B | 1,046.08B | 1,005.06B | 963.48B | 923.13B |
| Cost of Revenue | 1,431.51B | 1,244.07B | 1,106.85B | 994.31B | 1,089.76B | 659.69B | 495.92B | 558.76B | 535.41B | 520.99B | 490.26B | 447.63B | 433.19B | 317.58B | 285.06B | 289.54B | 278.63B | 279.66B | 282.10B | 279.18B | 269.40B | 300.34B | 337.85B | 384.01B | 432.33B |
| Gross Profit | 2,832.26B | 2,783.41B | 2,462.16B | 2,203.50B | 2,201.42B | 1,437.53B | 1,274.61B | 1,173.30B | 1,271.97B | 1,256.83B | 1,201.42B | 1,109.64B | 1,075.74B | 1,101.80B | 1,180.90B | 1,248.79B | 1,096.17B | 1,025.51B | 930.11B | 843.78B | 817.04B | 745.74B | 667.21B | 579.47B | 490.80B |
| Gross Profit Ratio | 66.43% | 69.11% | 68.99% | 68.91% | 66.89% | 68.54% | 71.99% | 67.74% | 70.38% | 70.70% | 71.02% | 71.26% | 71.29% | 77.63% | 80.55% | 81.18% | 79.73% | 78.57% | 76.73% | 75.14% | 75.20% | 71.29% | 66.38% | 60.14% | 53.17% |
| Research & Development | 729.92B | 633.33B | 526.09B | 455.83B | 492.38B | 368.30B | 325.44B | 312.30B | 345.93B | 382.10B | 341.56B | 324.29B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 499.40B | 450.96B | 811.62B | 810.71B | 640.20B | 666.68B | 834.23B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 385.96B | 0.00 | 319.36B |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 113.21B | 105.25B | 175.52B | 0.00 | 94.52B | 94.01B | 108.10B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 1,053.82B | 997.31B | 886.36B | 875.66B | 964.74B | 717.60B | 628.11B | 619.06B | 650.77B | 612.61B | 556.21B | 987.13B | 810.71B | 734.72B | 760.69B | 942.33B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 385.96B | 0.00 | 319.36B |
| Other Expenses | 834.44B | 662.27B | 588.87B | 362.74B | 643.90B | 908.87B | 707.38B | 705.13B | 795.22B | 1,003.99B | 720.59B | 5.81B | 0.00 | 3.78B | 735.00M | 12.13B | 673.05B | 567.01B | 527.30B | 458.50B | 445.40B | 435.05B | 0.00 | 353.37B | 0.00 |
| Operating Expenses | 2,618.18B | 2,292.90B | 2,001.32B | 1,694.24B | 2,101.02B | 1,277.17B | 1,032.82B | 1,017.43B | 1,141.15B | 1,386.09B | 1,062.15B | 987.13B | 810.71B | 734.72B | 760.69B | 942.33B | 673.05B | 567.01B | 527.30B | 458.50B | 445.40B | 435.05B | 385.96B | 353.37B | 319.36B |
| Cost & Expenses | 4,049.69B | 3,536.97B | 3,108.16B | 2,688.54B | 3,190.78B | 1,936.86B | 1,528.74B | 1,576.18B | 1,676.55B | 1,907.08B | 1,552.41B | 1,434.76B | 1,243.91B | 1,052.30B | 1,045.75B | 1,231.87B | 951.68B | 846.67B | 809.40B | 737.68B | 714.80B | 735.40B | 723.82B | 737.38B | 751.69B |
| Interest Income | 11.29B | 62.91B | 23.70B | 105.52B | 27.83B | 6.62B | 39.54B | 12.27B | 21.65B | 15.36B | 49.30B | 16.30B | 6.30B | 1.73B | 1.98B | 11.38B | 62.06B | 56.24B | 34.21B | 18.10B | 10.90B | 10.13B | 9.61B | 9.93B | 0.00 |
| Interest Expense | 119.54B | 169.70B | 166.61B | 248.63B | 165.01B | 48.16B | 31.93B | 23.25B | 31.93B | 32.88B | 30.72B | 3.32B | 1.88B | 1.34B | 1.43B | 1.62B | 333.00M | 247.00M | 365.00M | 334.00M | 359.00M | 420.00M | 759.00M | 1.02B | 1.19B |
| Depreciation & Amortization | 728.00B | 664.40B | 583.15B | 559.67B | 583.65B | 247.69B | 182.13B | 171.43B | 181.24B | 260.95B | 215.74B | 201.11B | 150.19B | 106.72B | 114.83B | 118.08B | 31.69B | 28.82B | 28.73B | 31.23B | 28.08B | 29.96B | 28.43B | 33.61B | 33.36B |
| EBITDA | 900.33B | 1,156.46B | 1,183.21B | 983.72B | 880.33B | 464.22B | 359.96B | 296.88B | 349.85B | 148.39B | 368.18B | 351.18B | 421.82B | 479.63B | 537.64B | 518.25B | 608.87B | 654.45B | 547.05B | 472.66B | 474.59B | 462.28B | 402.62B | 297.70B | 237.32B |
| EBITDA Ratio | 21.12% | 30.02% | 29.49% | 36.73% | 20.90% | 17.95% | 24.36% | 22.48% | 19.36% | 8.35% | 23.96% | 22.55% | 27.95% | 34.12% | 36.67% | 28.78% | 44.53% | 48.03% | 43.89% | 42.75% | 44.48% | 42.00% | 38.20% | 30.16% | 27.31% |
| Operating Income | 214.08B | 490.51B | 460.84B | 509.27B | 100.41B | 204.97B | 241.79B | 155.87B | 130.83B | -129.25B | 139.27B | 122.51B | 265.03B | 367.08B | 420.21B | 306.47B | 423.12B | 458.50B | 402.81B | 385.28B | 371.63B | 310.69B | 281.24B | 226.10B | 171.44B |
| Operating Income Ratio | 5.02% | 12.18% | 12.91% | 15.93% | 3.05% | 9.77% | 13.66% | 9.00% | 7.24% | -7.27% | 8.23% | 7.87% | 17.56% | 25.86% | 28.66% | 19.92% | 30.78% | 35.13% | 33.23% | 34.31% | 34.21% | 29.70% | 27.98% | 23.47% | 18.57% |
| Total Other Income/Expenses | -161.28B | -115.42B | -158.27B | -143.03B | -161.16B | -77.36B | -24.58B | -12.52B | -10.29B | -16.18B | -1.60B | 10.56B | -12.55B | 4.49B | -4.38B | 92.08B | 153.72B | 166.88B | 115.15B | 55.82B | 74.51B | 121.21B | 92.18B | 36.97B | 31.32B |
| Income Before Tax | 52.79B | 375.09B | 302.57B | 366.24B | -60.75B | 94.90B | 217.21B | 143.35B | 120.54B | -145.44B | 158.85B | 129.71B | 252.48B | 371.57B | 415.83B | 398.55B | 576.84B | 625.38B | 517.96B | 441.10B | 446.14B | 431.90B | 373.43B | 263.08B | 202.76B |
| Income Before Tax Ratio | 1.24% | 9.31% | 8.48% | 11.45% | -1.85% | 4.52% | 12.27% | 8.28% | 6.67% | -8.18% | 9.39% | 8.33% | 16.73% | 26.18% | 28.37% | 25.91% | 41.96% | 47.92% | 42.73% | 39.28% | 41.07% | 41.29% | 37.15% | 27.30% | 21.96% |
| Income Tax Expense | -91.41B | 58.05B | 72.41B | -9.94B | -105.04B | -14.12B | 30.50B | 27.83B | 37.06B | -2.40B | 49.29B | -3.88B | 125.21B | 121.33B | 115.67B | 161.35B | 218.77B | 285.84B | 201.36B | 160.23B | 157.91B | 157.49B | 134.89B | 114.15B | 81.45B |
| Net Income | 144.07B | 317.02B | 230.06B | 376.01B | 44.24B | 109.13B | 186.89B | 114.94B | 80.17B | -145.78B | 106.66B | 131.24B | 124.16B | 247.87B | 297.74B | 234.39B | 355.45B | 335.81B | 313.25B | 277.44B | 285.26B | 271.76B | 235.66B | 146.86B | 119.63B |
| Net Income Ratio | 3.38% | 7.87% | 6.45% | 11.76% | 1.34% | 5.20% | 10.56% | 6.64% | 4.44% | -8.20% | 6.30% | 8.43% | 8.23% | 17.46% | 20.31% | 15.24% | 25.85% | 25.73% | 25.84% | 24.71% | 26.26% | 25.98% | 23.45% | 15.24% | 12.96% |
| EPS | 91.16 | 204.29 | 147.14 | 240.72 | 28.41 | 56.75 | 119.67 | 73.58 | 51.13 | -92.69 | 67.55 | 94.11 | 78.65 | 157.01 | 188.60 | 144.91 | 209.49 | 193.00 | 176.74 | 156.51 | 160.93 | 153.82 | 133.51 | 83.20 | 67.78 |
| EPS Diluted | 91.16 | 201.94 | 145.87 | 238.96 | 28.25 | 56.43 | 118.78 | 73.13 | 50.86 | -92.69 | 67.47 | 94.09 | 78.63 | 156.98 | 188.57 | 144.90 | 209.49 | 193.00 | 176.74 | 156.51 | 160.93 | 153.82 | 133.51 | 83.20 | 67.78 |
| Weighted Avg Shares Out | 1.58B | 1.55B | 1.56B | 1.56B | 1.56B | 1.92B | 1.56B | 1.56B | 1.57B | 1.57B | 1.58B | 1.58B | 1.58B | 1.58B | 1.58B | 1.62B | 1.70B | 1.74B | 1.77B | 1.77B | 1.77B | 1.77B | 1.77B | 1.77B | 1.77B |
| Weighted Avg Shares Out (Dil) | 1.58B | 1.57B | 1.58B | 1.57B | 1.57B | 1.93B | 1.57B | 1.57B | 1.58B | 1.57B | 1.58B | 1.58B | 1.58B | 1.58B | 1.58B | 1.62B | 1.70B | 1.74B | 1.77B | 1.77B | 1.77B | 1.77B | 1.77B | 1.77B | 1.77B |
Takeda Receives Positive CHMP Opinion for Recombinant ADAMTS13 (rADAMTS13) in Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval, under exceptional circumstances, of recombinant ADAMTS13 (rADAMTS13) for the treatment of ADAMTS13 deficiency...
Takeda to Present Oncology Portfolio and Pipeline Data at the 2024 ASCO Annual Meeting
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE: 4502/NYSE:TAK) today announced that it will present data from its oncology pipeline and product portfolio at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO) being held May 31-June 4,...
AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer's Disease
OSAKA, Japan & CAMBRIDGE, Mass & LAUSANNE, Switzerland--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) and AC Immune SA (NASDAQ: ACIU) today announced an exclusive, worldwide option and license agreement for AC Immune's active immunotherapies targeting toxic forms of amyloid beta (Abeta), including ACI-24.060 for...
Takeda Pharmaceutical Company Limited (TAK) Fiscal Year 2023 Earnings Call Transcript
Takeda Pharmaceutical Company Limited (NYSE:TAK ) Fiscal Year 2023 Earnings Conference Call May 9, 2024 6:00 AM ET Company Participants Christopher O'Reilly – Head-Investor Relations Christophe Weber – President and Chief Executive Officer Andy Plump – President of R&D Milano...
Takeda Pharmaceuticals earnings: profits, EPS down over 50% in Q4 financial results
Japanese pharmaceutical titan Takeda (NYSE: TAK/TSE: 4502) today announced their financial results for Q4 and the full fiscal year of 2023. The company described it in a press release as “a year of significant loss-of-exclusivity impact”, a grim picture which...
Japan's Takeda Pharma says full-year profit slumps 56%
Japan's Takeda Pharmaceutical said full-year earnings slumped by 56% as the company focused on rebuilding its drug pipeline to make up for the loss of patent protection for major sellers.
Down -6.19% in 4 Weeks, Here's Why Takeda Pharmaceutical Co. (TAK) Looks Ripe for a Turnaround
Takeda Pharmaceutical Co. (TAK) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Down -5.9% in 4 Weeks, Here's Why Takeda Pharmaceutical Co. (TAK) Looks Ripe for a Turnaround
Takeda Pharmaceutical Co. (TAK) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of fruquintinib, a selective inhibitor of vascular endothelial growth factor receptors (VEGFR) -1,...
All You Need to Know About Takeda Pharmaceutical Co. (TAK) Rating Upgrade to Strong Buy
Takeda Pharmaceutical Co. (TAK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Source: https://incomestatements.info
Category: Stock Reports